ILLUMINA, INC. — Director's Dealing 2017

Dec 13, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ILLUMINA INC (ILMN)
CIK: 0001110803
Period of Report: 2017-12-11

Reporting Person: Hampton Malcolm Garret (EVP Clinical Genomics Group)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-12-11	Common Stock	A	2920	—	Acquired	6453	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-12-11	Performance Shares	$	A	8758	Acquired	2021-01-03	Common Stock (8758)	Direct

Footnotes

F1: Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of November 5, 2018, November 5, 2019, November 5, 2020, and November 5, 2021, subject to awardee's continuing status as a service provider on such dates.

F2: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 3, 2021. The number of shares issued will range from 0% to 150% of the amount specified above, based on the Company's actual earnings per share for the fiscal year ending January 3, 2021, relative to pre-defined objectives, subject to awardee's continuing to be a service provider on such dates.